University of Washington School of Pharmacy’s Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute and the Institute for Clinical and Economic Review Collaboration
The University of Washington School of Pharmacy (UWSOP) and the Institute for Clinical and Economic Review (ICER) have a partnership to leverage UWSOP’s expertise in economic modeling of pharmaceutical interventions to support ICER’s growing body of work in new drug assessments. UWSOP’s Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute provides health economic consulting support to ICER for use in ICER’s reports for its drug assessment program. CHOICE is internationally renowned for its excellence in health economics and cost-effectiveness modeling, and ICER is a leader in producing reports that address the clinical effectiveness, cost-effectiveness, and potential budgetary impact of high-profile interventions. As part of the agreement, UWSOP’s researchers will develop cost-effectiveness models for several soon-to-be or recently FDA approved drugs, leveraging evidence synthesis work performed by ICER, data supplied by stakeholders, and publicly-available data.